B. Muresan

发表

An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia

J. Cappelleri, E. Leip, B. Heeg, 2018, Current medical research and opinion.

TITLE: Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Gabriela, Henríquez, B. Weinstein, 2021 .

Comparison of efficacy from two different dosing regimens of bortezomib: an exposure–response analysis

M. Dimopoulos, J. San-Miguel, M. Mateos, 2020, British journal of haematology.

Efficacy and Safety of Experimental versus Approved CAR T-cell Therapies in Large B-cell Lymphoma Using Matching Adjusted Indirect Comparisons: A Systematic Review and Meta-Analysis Protocol

Yuchen Su, C. Camargo, D. Carpenter, 2021, Principles and Practice of Clinical Research Journal.

Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review.

Gabriela Henríquez, B. Weinstein, D. Carpenter, 2021, medRxiv.

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

Antonio Vaz de Macedo, Gabriela Henríquez, Yu-Chen Su, 2021, Innovations in pharmacy.

Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review.

J. Cappelleri, B. Heeg, A. Gezin, 2022, Future oncology.

Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France

E. Fenu, R. Turpin, M. Oppe, 2022, Expert review of pharmacoeconomics & outcomes research.

Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting

J. Cappelleri, B. Heeg, C. Mamolo, 2021, Applied Health Economics and Health Policy.

Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia

J. Cortes, J. Cappelleri, C. Gambacorti-Passerini, 2019, Current medical research and opinion.

Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.

T. Ziemssen, J. Alexander, A. Kurzeja, 2021, Neurodegenerative disease management.

An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia

J. Cappelleri, E. Leip, B. Heeg, 2021, Current Medical Research and Opinion.

TITLE: Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Gabriela, Henríquez, B. Weinstein, 2021 .